About the deal

Investec acts as Sole Financial Advisor on Dechra’s £4.5bn cash offer by Private Equity firm EQT.

Dechra became a Corporate Broking client of Investec in April 2009, appointing us as their Sole Financial advisor and Sole Corporate Broker, a role we’ve held ever since. Now valued at £4.5bn by EQT, that’s a x18 increase in the 14 years since they became our client. This growth story led to them entering the FTSE 100 in 2022 and is a clear demonstration of Investec supporting clients with high growth ambitions.

This is the largest M&A transaction in the UK so far this year and completion is expected during Q4 2023.

Ian Page, CEO at Dechra Pharmaceuticals said: “Headed by Chris Treneman, Investec has been a long-standing partner of ours, successfully supporting Dechra on some of our most important corporate activities both from an M&A and equity capital markets perspective. Its role as sole advisor on this landmark deal for Dechra reflects the quality and consistency of service and advice we’ve received over many years.“
 
Jonathan Arrowsmith, Head of Investment Banking at Investec said: “We have been working with Dechra for 14 years, during which time it has grown from a market cap of £255m to its sale for c£4.5bn to a global private equity firm. This is a hugely important deal for Dechra and is testament to the tremendous business the management has built. It is also a very significant milestone for Investec in terms of the quality and ambitions of the M&A business we are building.”

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Their expertise is in the development, manufacture, sales and marketing of high-quality products exclusively for veterinarians worldwide. Dechra’s products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.

The Company sells its products via a distributor network across 88 countries.